Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Benjamin

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Trials|May 26, 2026
A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)-protocol for a phase 3 clinical trialEdgardo F Cartagena Ayala, Lumen Vera Colon, Yesim Aydinok, et al.
Blood|May 13, 2004
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialJeffrey McCullough, David H Vesole, Richard J Benjamin, et al.
Blood Advances|March 6, 2024
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet componentsAllison P Wheeler, Edward L Snyder, Majed Refaai, et al.
Trials|December 12, 2023
Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trialEdward L Snyder, Michael E Sekela, Ian J Welsby, et al.
Transfusion|June 24, 2022
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet componentsEdward L Snyder, Allison P Wheeler, Majed Refaai, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Trials|May 26, 2026
A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)-protocol for a phase 3 clinical trialEdgardo F Cartagena Ayala, Lumen Vera Colon, Yesim Aydinok, et al.
Blood|May 13, 2004
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialJeffrey McCullough, David H Vesole, Richard J Benjamin, et al.
Blood Advances|March 6, 2024
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet componentsAllison P Wheeler, Edward L Snyder, Majed Refaai, et al.
Trials|December 12, 2023
Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trialEdward L Snyder, Michael E Sekela, Ian J Welsby, et al.
Transfusion|June 24, 2022
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet componentsEdward L Snyder, Allison P Wheeler, Majed Refaai, et al.
Pageof 9